Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.ajo.2013.08.004
DC Field | Value | |
---|---|---|
dc.title | Cost-effectiveness of osteo-odonto keratoprosthesis in Singapore | |
dc.contributor.author | Dong, D. | |
dc.contributor.author | Tan, A. | |
dc.contributor.author | Mehta, J.S. | |
dc.contributor.author | Tan, D. | |
dc.contributor.author | Finkelstein, E.A. | |
dc.date.accessioned | 2014-11-26T08:27:23Z | |
dc.date.available | 2014-11-26T08:27:23Z | |
dc.date.issued | 2014-01 | |
dc.identifier.citation | Dong, D., Tan, A., Mehta, J.S., Tan, D., Finkelstein, E.A. (2014-01). Cost-effectiveness of osteo-odonto keratoprosthesis in Singapore. American Journal of Ophthalmology 157 (1) : 78-84.e2. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ajo.2013.08.004 | |
dc.identifier.issn | 00029394 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/109996 | |
dc.description.abstract | Purpose To determine the long-term cost-effectiveness of osteo-odonto keratoprosthesis (OOKP) relative to no treatment among patients with end-stage corneal and ocular surface diseases in Singapore. Design Cost-effectiveness analysis based on data from a retrospective cohort study. Methods From a health system perspective, we calculated the incremental cost-effectiveness ratio of OOKP treatment relative to no treatment over a 30-year horizon, based on data from a cohort of 23 patients who underwent OOKP surgery between 2004 and 2009 at Singapore National Eye Centre. Preoperative and postoperative vision-related quality-of-life values were estimated from patients' visual outcomes and were used to calculate the gain in quality-adjusted life years (QALYs) resulting from OOKP treatment. Unsubsidized costs for surgery, consultations, examinations, medications, follow-up visits, and treatments for complications were retrieved from patients' bills to estimate the total costs associated with OOKP treatment. Sensitivity analyses were conducted to test the robustness of the model. Results Over a 30-year period, OOKP treatment, compared with no treatment, improved QALYs by 3.991 among patients with end-stage corneal and ocular surface diseases at an additional cost of S$67 840 (US$55 150), resulting in an incremental cost-effectiveness ratio of S$17 000/QALY (US$13 820/QALY). Conclusions Based on commonly cited cost-effectiveness benchmarks, the OOKP is a cost-effective treatment for patients with end-stage corneal and ocular surface diseases. © 2014 by Elsevier Inc. All rights reserved. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ajo.2013.08.004 | |
dc.source | Scopus | |
dc.type | Article | |
dc.contributor.department | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE | |
dc.description.doi | 10.1016/j.ajo.2013.08.004 | |
dc.description.sourcetitle | American Journal of Ophthalmology | |
dc.description.volume | 157 | |
dc.description.issue | 1 | |
dc.description.page | 78-84.e2 | |
dc.description.coden | AJOPA | |
dc.identifier.isiut | 000329273000013 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.